Sales & Marketing Media Partner Why BIO-Europe 2026 matters: The evolution of strategic biop... 2026 marks a significant evolution for BIO-Europe.
News Sandoz adds 10 biosimilars through $322m Henlius deal Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.
Oncology Sponsored Establishing ctDNA as a validated primary surrogate endpoint Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
Oncology EGFR-mutant lung cancer: Cracking the drug resistance code Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade.
R&D Go north: Life sciences excellence shines bright in Sweden Gothenburg is Sweden's fastest-growing and second largest city region and one of Europe's leading innovation regions.
Digital The real test for healthtech companies isn’t innovation – it... The Basel Area is increasingly becoming a convergence point where life sciences, advanced computing, and health technology intersect.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
